Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 8/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | DRD3 | P35462 | 3/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1654652 | 0.94 | DRD2 (0.52) | DRD2SIGMAR1DRD3FAAH | |
| SCHEMBL27934814 | 0.94 | DRD2 (0.50) | DRD2SIGMAR1DRD3 | |
| SCHEMBL10012965 | 0.86 | DRD2 (0.43) | DRD2SIGMAR1DRD3 | |
| SCHEMBL10011586 | 0.83 | DRD2 (0.41) | DRD2DRD3 | |
| SCHEMBL1654200 | 0.81 | CYP3A4 (0.47) | — | |
| SCHEMBL12781936 | 0.80 | DRD2 (0.41) | DRD2SIGMAR1DRD3 | |
| SCHEMBL1655557 | 0.76 | CYP3A4 (0.42) | — | |
| SCHEMBL10013000 | 0.75 | CYP3A4 (0.46) | — | |
| SCHEMBL27935081 | 0.75 | CYP3A4 (0.46) | — | |
| SCHEMBL17861451 | 0.74 | DRD2 (0.60) | DRD2DRD3FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112358477-A | Medicine for treating cholecystitis and preparation method thereof | 牡丹江医学院 | 2021-02-12 | — | — | CN | disclosed |
| EP-2488521-B1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND (IE) | 2013-12-18 | — | — | EP | disclosed |
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-11-07 | — | — | US | disclosed |
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-11-07 | — | — | US | disclosed |
| US-8497270-B2 | Macrocyclic integrase inhibitors | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2487176-A1 | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus | Elanco Animal Health Ireland Limited (IE) | 2012-08-15 | — | — | EP | disclosed |
| EP-2487176-A1 | Macrocyclic integrase inhibitors for use in the treatment of feline immunodeficiency virus | Elanco Animal Health Ireland Limited (IE) | 2012-08-15 | — | — | EP | disclosed |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-07-05 | — | — | US | disclosed |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | ELANCO ANIMAL HEALTH IRELAND LIMITED (US) | 2012-07-05 | — | — | US | disclosed |
| WO-2011045330-A1 | MACROCYCLIC INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS (IE) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296330-A1 | MACROCYCLIC INTEGRASE INHIBITORS FOR USE IN THE TREATMENT OF FELINE IMMUNODEFICIENCY VIRUS | FIP1L1, PIM1, TYMP | DRD2 3987/4885SIGMAR1 4728/4885DRD3 3718/4885 |
| US-20120172367-A1 | MACROCYCLIC INTEGRASE INHIBITORS | CCNI, CCNY, CDK7 | DRD2 2919/4885SIGMAR1 2649/4885DRD3 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.